Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Payables (2016 - 2025)

Historic Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $10.1 million.

  • Viridian Therapeutics, Inc.\DE's Payables rose 5877.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 5877.25%. This contributed to the annual value of $2.1 million for FY2024, which is 428.76% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Payables stood at $10.1 million for Q3 2025, which was up 5877.25% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Payables ranged from a high of $14.2 million in Q4 2022 and a low of $2.1 million during Q4 2024
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Payables had a median value of $3.7 million in 2023 and averaged $5.2 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 51116.36% in 2022, then plummeted by 8427.01% in 2023.
  • Viridian Therapeutics, Inc.\DE's Payables (Quarter) stood at $2.3 million in 2021, then skyrocketed by 511.16% to $14.2 million in 2022, then tumbled by 84.27% to $2.2 million in 2023, then fell by 4.29% to $2.1 million in 2024, then soared by 369.58% to $10.1 million in 2025.
  • Its Payables stands at $10.1 million for Q3 2025, versus $8.5 million for Q2 2025 and $3.9 million for Q1 2025.